In back-to-back tri­al dis­as­ters, Gem­phire now says it shut­tered a tri­al af­ter see­ing pa­tients' fat­ty liv­er dis­ease get worse

Four days af­ter Gem­phire saw its shares $GEMP crushed by news of an FDA de­mand for ad­di­tion­al safe­ty da­ta on its on­ly drug be­fore ad­vanc­ing it in­to Phase III, the biotech is back with more bad, ter­ri­ble, ab­solute­ly no good news.

A Phase IIa study for gem­cabene in pe­di­atric pa­tients with non-al­co­holic fat­ty liv­er dis­ease, or NAFLD, has been scrapped af­ter in­ves­ti­ga­tors de­ter­mined that the first three pa­tients got worse af­ter be­ing dosed. And an­oth­er mid-stage study is un­der close re­view to see if the biotech needs to shut­ter it as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER